Digital Pathology Market Advances With Remote Diagnostic Collaboration

The global digital pathology market was valued at USD 1.39 billion in 2024 and is projected to reach USD 2.97 billion by 2033, expanding at a CAGR of 8.6% from 2025 to 2033. This growth is primarily driven by the rising prevalence of cancer, increasing emphasis on workflow efficiency, and the growing demand for faster and more accurate diagnostic tools.

Key Market Trends & Insights

• North America dominated the global digital pathology market in 2024 with a 40.10% share.
• Asia Pacific is expected to witness the fastest CAGR from 2025 to 2033.
• By type, the human pathology segment held the largest share of 89.92% in 2024.
• By product, the software segment accounted for the highest share at 43.86% in 2024.
• By application, the academic research segment emerged as the leading segment in 2024.

Market Size & Forecast

• 2024 Market Size: USD 1.39 Billion
• 2033 Market Size Projection: USD 2.97 Billion
• CAGR (2025–2033): 8.6%
• 2024 Regional Leader: North America

The market continues to grow due to increased healthcare investments, rising adoption of telepathology, and an expanding focus on drug discovery and precision medicine. Major companies are launching innovative solutions and expanding their offerings to gain a competitive edge.

The prevalence of chronic diseases, particularly cancer, remains a crucial growth driver. With the rising incidence of cancer, pathologists increasingly require comprehensive data to personalize treatment approaches. Digital pathology plays a vital role by accelerating diagnosis, enhancing accuracy, and offering improved therapeutic insights. For instance, a 2024 study published in Breast Cancer Research highlighted the use of deep learning models—including ResNet50, Transformer, and Hover-net—to support image enhancement, segmentation, and classification in breast cancer diagnostics.

Growing adoption of healthcare IT solutions is also contributing significantly to market expansion. Organizations are embracing digital pathology technologies to reduce operational costs, streamline workflows, overcome staffing limitations, and support efficient data sharing. The rise in teleconsultations, increased use in companion diagnostics, and broader applications in drug discovery further boost market growth.

Simultaneously, AI integration is transforming image analysis by automating the identification of critical tissue regions, reducing manual workloads, minimizing human error, and driving automation across pathology workflows.

Order a free sample PDF of the Digital Pathology Market Intelligence Study, published by Grand View Research.

Key Digital Pathology Companies

Major market participants are engaging in strategic expansions, partnerships, and product innovations to strengthen their global presence.

Key Digital Pathology Companies Insights

Key players operating in the digital pathology market are undertaking various initiatives to strengthen their presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling the market growth.

Key Digital Pathology Companies:

The following are the leading companies in the digital pathology market. These companies collectively hold the largest market share and dictate industry trends.

• Leica Biosystems Nussloch GmbH (Danaher)
• Hamamatsu Photonics, Inc.
• Koninklijke Philips N.V.
• Olympus Corporation
• Hoffmann-La Roche Ltd.
• Mikroscan Technologies, Inc.
• Epredia (3DHISTECH Ltd.)
• Visiopharm A/S
• Huron Technologies International Inc.
• ContextVision AB
• HANGZHOU ZHIWEI INFORMATION TECHNOLOGY CO. LTD. (MORPHOGO)
• West Medica Produktions- und Handels- GmbH (West Medica)
• aetherAI
• IBEX (IBEX MEDICAL ANALYTICS)
• SigTuple Technologies Private Limited
• Morphle Labs, Inc
• Bionovation Biotech, Inc.
• Inspirata, Inc
• Scopio labs
• Path Hub
• Sectra AB
• Agfa-Gevaert Group
• OptraScan
• Agilent Technologies, Inc.
• KFBIO
• CellaVision

Some of the key players in the AI in digital pathology market:

• Aiosyn
• Proscia Inc
• EVIDENT
• Aignostics, Inc.
• Aiforia
• Dedalus S.p.A
• Qritive
• Mindpeak GmbH
• CGI Inc.
• Gestalt

Conclusion

The global digital pathology market is undergoing rapid transformation driven by cancer diagnostics needs, rising healthcare digitalization, and accelerated adoption of AI-powered imaging tools. With strong regional growth in Asia Pacific and continuous technological advancements, the market is expected to experience sustained expansion through 2033. Increasing integration of AI, telepathology, and software-driven diagnostics will continue to enhance efficiency, reduce diagnostic errors, and support personalized medicine—solidifying digital pathology as a critical component of modern healthcare systems.

Explore Horizon Databook – The world’s most expansive market intelligence platform developed by Grand View Research.